Juno Bio Secures $3.8 Million to Enhance Vaginal Health Diagnostics
Oakland, CA – Juno Bio, a startup focused on women’s health, has successfully raised $3.8 million from investors including Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator. This funding aims to improve precision testing for the vaginal microbiome.
The company reports that 67.5% of patients using its platform had been misdiagnosed, underdiagnosed, or overdiagnosed prior to using Juno Bio’s services. In response, the startup has opened its first CLIA-certified lab in Oakland, which will exclusively handle women’s health diagnostics.
Rethinking Vaginal Health Care
Visits to the doctor for vaginal infections often end without clear answers. Traditionally, patients face swabs, guesswork, and prescriptions that may miss the mark. Juno Bio, co-founded by Hana Janebdar and Dr. Leighton Turner in 2018, aims to address the significant gaps in diagnostics for vaginal health.
Their data shows that only 13% of patients received correct treatment when relying on standard approaches, while many were sidelined with co-infections that typical tests overlooked. Juno Bio’s advanced sequencing technology screens for about 10,000 types of bacteria and fungi, along with four common STIs, differentiating between conditions that may look similar under a microscope.
A Growing Competitive Field
Juno Bio is not the only player in the vaginal health market. For example, New York-based Evvy has raised $19 million and is also utilizing similar sequencing techniques. Another competitor, Daye, is exploring a tampon-based testing method. While these rivals focus on consumer wellness, Juno Bio aims to be a foundational player in clinical settings, supporting healthcare providers and pharmaceutical research.
Check Warner from Ada Ventures praised Juno Bio’s innovative approach and efficient use of funding, emphasizing that their work is essential in a field historically lacking attention.
Next Steps and Market Potential
Juno Bio sees this funding round as a chance to grow, making actionable care more accessible and addressing the gender health gap. Since launching, they have sold over 20,000 testing kits and established one of the largest databases for vaginal microbiome health.
The broader market for precision medicine is anticipated to expand significantly—from around $112 billion in 2025 to over $207 billion by 2030—focusing on areas like fertility and reproductive health.
While the challenge remains whether improved diagnostic methods can effectively reduce the high misdiagnosis rates, Juno Bio believes that better data could be the key to the transformation healthcare has long needed.
